A Study to Compare Elacestrant vs. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer

Overview

About this study

The purpose of this study is to compare the effectiveness and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhibitor in combination with fulvestrant or an aromatase inhibitor (AI) .

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria:

  • Subjects with proven diagnosis of adenocarcinoma of the breast with evidence of either locally advanced disease not amenable to resection or radiation therapy with curative intent or metastatic disease not amenable to curative therapy. 
  • Subjects must be appropriate candidates for endocrine monotherapy.
  • Subjects must have measurable disease or, nonmeasurable (evaluable) bone-only disease.
  • Female or male subjects age ≥ 18 years.
  • Female subjects must be postmenopausal women.
  • Male subjects must not allow pregnancy with their sperm (abstain, do not donate sperm, etc.). 
  • Subjects must have ER+/HER2-tumor status.
  • Subjects must have previously received at least one and no more than two lines of endocrine therapy for advanced/metastatic breast cancer and meet additional previous treatment criteria.
  • Subjects must have received prior treatment with a CDK4/6 inhibitor in combination with either fulvestrant or an aromatase inhibitor (AI). 
  • Subjects may have received no more than one line of chemotherapy in the advanced/metastatic setting. 
  • Subjects must have ctDNA ESR1-mut or ESR1-WT status as determined by central testing before subject is randomized.

Exclusion Criteria: 

  • Prior treatment with elacestrant, GDC-0810, GDC-0927, GDC-9545, LSZ102, AZD9496, bazedoxifene, or other investigational SERD or investigational ER antagonist. 
  • Prior anticancer or investigational drug treatment within the following windows:
    • Fulvestrant treatment < 28 days before first dose of study drug.
    • Any endocrine therapy < 14 days before first dose of study drug (with the exception of GnRH agonist therapy in male subjects).
    • Chemotherapy < 21 days before first dose of study drug.
    • Any investigational anti-cancer drug therapy < 28 days or five half-lives (whichever is shorter) before the first dose of study drug. Enrollment of subjects whose most recent therapy was an investigational agent should be discussed with the Sponsor 3. Presence of symptomatic visceral disease as defined in protocol.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Karthik Giridhar, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions